Treats advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a…. Sold as Bizengri. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Zenocutuzumab-Zbco (sold as Bizengri), first approved Dec 4, 2024, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| BIZENGRI | Part B | $3.3M | New | 24 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 4, 2024 | BizengriBLA 761352 · New molecular entity | Merus N.V. | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
